Costs, benefits, and effectiveness of interventions for the prevention, treatment, and control of cardiovascular diseases and diabetes in Africa

Progress in Cardiovascular Diseases

Volumn 56, Issue 3, 2013, Pages 314-321

  Mendis, Shanthi ^a   Chestnov, Oleg ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cardiovascular disease; Cost; Cost effectiveness; Diabetes; NCD

Indexed keywords

AFRICA; ARTICLE; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE CONTROL; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; LOWEST INCOME GROUP; NON COMMUNICABLE DISEASE; PROPHYLAXIS; RESOURCE ALLOCATION;

CARDIOVASCULAR DISEASE; COST; COST EFFECTIVENESS; DIABETES; NCD; NONCOMMUNICABLE DISEASE;

AFRICA; CARDIOVASCULAR DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DIABETES MELLITUS; HEALTH POLICY; HUMANS; MORBIDITY;

EID: 84887949521     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2013.09.001     Document Type: Article

References (49)

1. Causes of death 2008: data sources and methods (online database), Geneva, World Health Organization Accessed 1st July 2013. http://www.who.int/healthinfo/global_burden_disease/cod_2008_sources_methods.pdf.
2. World Health Organization Global status report on noncommunicable diseases 2010 2010, World Health Organization, Geneva.
3. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, World Health Organization http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf.
4. World Health Statistics Part II highlighted topics 2012, World Health Organization, Geneva.
5. United Nations General Assembly resolution 66/2 political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases Accessed 1st July 2013. http://www.who.int/nmh/events/un_ncd_summit2011/political_declaration_en.pdf.
6. World Health Assembly Global action plan for the prevention and control of NCD 2013-2020 2013, World Health Organization, Geneva, (WHA 66.10).
7. World Health Report Primary health care - now more than ever 2008, World Health Organization, Geneva.
8. Heath Report World Health systems financing: the path to universal coverage 2010, World Health Organization, Geneva.
9. World Health Organization Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk 2007, Geneva, Switzerland.
10. World Health Organization Prevention of recurrent heart attacks and strokes in low and middle income populations: evidence-based recommendations for policy makers and health professionals 2003, Geneva, Switzerland.
11. Disease control priorities in developing countries 2006, Oxford University Press, New York. D.T. Jamison, J.G. Breman, A.R. Measham (Eds.).
12. World Health Organization Prevention and control of noncommunicable diseases: guidelines for primary health care in low-resource settings; diagnosis and management of type 2 diabetes and management of asthma and chronic obstructive pulmonary disease 2012, Geneva, Switzerland.
13. World Health Organization Scaling up action against noncommunicable disease: how much will it cost? Geneva, Switzerland Accessed 1st July 2011. http://whqlibdoc.who.int/publications/2011/9789241502313_eng.pdf.
14. Ortegon M., Lim S., Chisholm D., et al. Cost effectiveness of strategies to control cardiovascular disease, diabetes and tobacco us in sub-Saharan Africa and South East Asia: mathematical modeling study. BMJ 2013, 344:e607.
15. Jha P., Chaloupka F.J., Moore J., et al. Tobacco addiction. Disease control priorities in developing countries 2006, World Bank, Washington DC. D.T. Jamison, J.G. Breman, A.R. Measham (Eds.).
16. Conference of the parties to the WHO framework convention on tobacco control. Geneva, World Health Organization Accessed 1st July 2013. http://www.who.int/gb/fctc/PDF/cop2/FCTC_COP2_17P-en.pdf.
17. World Health Organization WHO technical manual on tobacco tax administration 2010, Geneva, Switzerland.
18. World Health Organization Protection from exposure to second-hand tobacco smoke: policy recommendations 2007, Geneva, Switzerland.
19. International Tobacco Control Policy Evaluation Project Key findings 2010, Waterloo, International Tobacco Control Project.
20. Hoek J., Wilson N., Allen M., et al. Lessons from New Zealand's introduction of pictorial health warnings on tobacco packaging. Bull World Health Organ 2010, 88:861-866.
21. Tobacco advertising: economic theory and international evidence 1999, National Bureau of Economic Research, Cambridge.
22. World Health Organization WHO/TFI smoking cessation 2011, Geneva, Switzerland.
23. Anderson P., Chisholm D., Fuhr D. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet 2009, 373:2234-2246.
24. World Health Organization Regional Office for Europe Evidence for the effectiveness and cost-effectiveness of interventions to reduce alcohol-related harm 2009, Copenhagen, Denmark.
25. Health Assembly World Global strategy to reduce the harmful use of alcohol 2010, World Health Organization, Geneva, (WHA 63.13).
26. Murray C.J., Lauer J.A., Hutubessy R.C., et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003, 361:717-725.
27. Willett W.C., Koplan J.P., Nugent R., et al. Prevention of chronic disease by means of diet and lifestyle changes. Disease Control Priorities in Developing Countries 2006, World Bank. D.T. Jamison, J.G. Breman, A.R. Measham (Eds.).
28. A global brief on hypertension; silent killer, global public health crisis 2013, World Health Organization.
29. Reducing salt intake in populations 2006, World Health Organization.
30. Asaria P., Chisholm D., Mathers C., et al. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 2007, 370:2044-2053.
31. Webster J.L., Dunford E.K., Hawkes C., et al. Salt reduction initiatives around the world. J Hypertens 2011, 29(6):1043-1050.
32. L'Abbé M.R., Stender S., Skeaff M., et al. Approaches to removing trans fats from the food supply in industrialized and developing countries. Eur J Clin Nutr 2009, 63:S50-S67.
33. World Health Organization Interventions on diet and physical activity: what works: summary report 2009, Geneva, Switzerland.
34. Cecchini M., Sassi F., Lauer J.A., et al. Tackling unhealthy diets, physical inactivity, and obesity: health effects and cost effectiveness. Lancet 2010, 376:1775-1784.
35. Health Assembly World Global strategy on diet, physical activity and health. (WHA 57.17) 2004, World Health Organization, Geneva, (WHA 57.17).
36. World Health Organization The extent, nature and effects of food promotion to children: a review of the evidence 2006, Geneva, Switzerland.
37. World Health Assembly Marketing of food and non-alcoholic beverages to children 2010, World Health Organization, Geneva, (WHA63.14).
38. Ramachandran A., Snehalatha C., Mary S., et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP). Diabetologia 2006, 49:289-297.
39. Lim S.S., Gaziano T.A., Gakidou E., et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007, 370:2054-2062.
40. World Health Organization Package of essential noncommunicable (WHO-PEN) disease interventions for primary health care in low resource settings 2011, Geneva, Switzertland.
41. Ndindjock R., Gedeon J., Mendis S., et al. Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles. Bull World Health Organ 2011 Apr 1, 89(4):286-295.
42. Mendis S., Johnston S.C., Fan W., et al. Cardiovascular risk management and its impact on hypertension control in primary care in low-resource settings: a cluster-randomized trial. Bull World Health Organ 2010, 288:412-419.
43. Abegunde D.O., Shengelia B., Luyten A., et al. Can non-physician health-care workers assess and manage cardiovascular risk in primary care?. Bull World Health Organ 2007, 85:432-440.
44. Mendis S., Al Bashir I., Dissanayake L., et al. Gaps in capacity in primary care in low-resource settings for implementation of essential noncommunicable disease interventions. Int J Hypertens 2012, 58:40-41.
45. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 (First International Study of Infarct Survival Collaborative Group). Lancet 1986, 2:57-66. ISIS-1 (First International Study of Infarct Survival) Collaborative Group.
46. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. The Lancet, 2:349-360.
47. World Health Organization Rheumatic fever and rheumatic heart disease. WHO technical report 923 2001, Geneva, Switzerland.
48. Li R., Zhang P., Barker L.E., et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010, 33:1872-1894.
49. Mensah G.A., Mayosi B.M. The 2011 United Nations high-level meeting on non-communicable diseases: the Africa agenda calls for a 5-by-5 approach. S Afr Med J 2012 Nov 8, 103(2):77-79.